Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
With its increasing prevalence in every continent diabetes mellitus (DM) is a common chronic disease that affects millions of people worldwide. Today, there is huge interest within the scientific community to ameliorate the complications caused by diabetes and its various treatments. Although, cardiovascular diseases, chronic kidney failure, retinopathy and peripheral neuropathy have been widely investigated, physicians also recognize that there are sexual problems prevalent in diabetic men and women. Unfortunately, some of the diabetologist still underestimate the sexual health issues of diabetic patients, which is associated with significant decrease in patients' quality of life. However, health care professionals must remember that for some having a good sexual performance and happy relationship is much more important than regulating their blood sugar or reducing their HbA1C levels.
At the European Society of Sexual Medicine (ESSM) annual meeting in November 2007, Eli Lilly and Company sponsored a symposium entitled ‘Cardiac sexology: can we save a patient's life and his love life?’ The aim of this meeting was not only to give participants valuable information about the etiologic links between erectile dysfunction (ED) and cardiovascular disease (CVD), but also to provide a glance into a future that I would like to call ‘Cardiac Sexology’ and how this might affect clinical practice.
The University of Texas Medical Branch in Galveston, Texas, organized the very first conference on the association between sexual dysfunction and heart diseases, entitled 'Sex and the Heart', which was held April 23, 2005 at the Galveston Convention Center at the Texas gulf coast.
The Forum on Men's Health in ED is an initiative of the Spanish Association of Andrology (ASESA) in cooperation with the Spanish Association of Urology (AEU), and includes the participation of nine scientific societies, as well as the Madrid Official Association of Pharmacists.
At this closed symposium, sponsored by Bayer and GlaxoSmithKline, various aspects of the biology and pharmacology of NO/cGMP signaling and PDE5 were discussed, with special emphasis on newer PDE5 inhibitors and potential new therapeutics focused on NO signaling, especially endothelial and neuronal NO synthases.